Original Article

Pediatrics

Check for updates

Prevalence of Pathological Brain Lesions in Girls with Central Precocious Puberty: Possible Overestimation?

Jong Seo Yoon, Cheol Hwan So, Hae Sang Lee, Jung Sub Lim, and Jin Soon Hwang

Department of Pediatrics, Ajou University School of Medicine, Ajou University Hospital, Suwon, Korea

Address for Correspondence:
Jin Soon Hwang, MD, PhD
Department of Pediatrics, Ajou University School of Medicine, Ajou University Hospital, 164 World Cup-ro, Yeongtong-gu, Suwon 16499, Republic of Korea.
E-mail: pedhwang@ajou.ac.kr

© 2018 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID IDs
Jong Seo Yoon
https://orcid.org/0000-0003-2331-1680
Cheol Hwan So
https://orcid.org/0000-0003-1759-0003
Hae Sang Lee
https://orcid.org/0000-0002-9684-4042
Jung Sub Lim
https://orcid.org/0000-0001-9560-8921
Jin Soon Hwang
https://orcid.org/0000-0002-2666-3801

Disclosure
The authors have no potential conflicts of interest to disclose.

ABSTRACT

Background: Brain magnetic resonance imaging (MRI) is routinely performed to identify brain lesions in girls with central precocious puberty (CPP). We aimed to investigate the prevalence and type of brain lesions among Korean girls with CPP and evaluate the need for routine brain MRI examinations.

Methods: This retrospective cross-sectional study evaluated data on 3,528 girls diagnosed with CPP from April 2003 to December 2016, and identified 317 girls who underwent sellar MRI. Exclusion criteria were patients with a known brain tumor or who did not undergo brain MRI due to refusal or the decision of the pediatric endocrinologist.

Results: Normal sellar MRI findings were observed in 291 of the 317 girls (91.8%). Incidental findings were observed in 26 girls (8.2%). None of the patients had pathological brain lesions.

Conclusion: The prevalence of intracranial lesions among girls who were generally healthy and without neurological symptoms but diagnosed with CPP was lower than that previously reported. Furthermore, none of the identified lesions required treatment. It may be prudent to reconsider the routine use of brain MRI to screen all patients with CPP, especially if they are healthy and neurologically asymptomatic, and are girls aged 6–8 years.

Keywords: Girl; Precocious Puberty; Brain; Magnetic Resonance Imaging; Prevalence; Brain Neoplasm

INTRODUCTION

Central precocious puberty (CPP) is the onset of secondary sexual characteristics before age 8 years for girls and age 9 years for boys, and is caused by the early activation of the hypothalamic-pituitary-gonadal axis. Although approximately 90% of girls have idiopathic CPP, approximately 40%–75% of boys with CPP have a pathological brain lesion. Therefore, brain magnetic resonance imaging (MRI) may be used to screen children with CPP to exclude the possibility of a pathological brain lesion. Numerous studies have evaluated the prevalence and types of intracranial lesions in CPP cases, as well as their clinical and biochemical predictors. However, there is controversy regarding the necessity of MRI, and there are no...
consistent markers for the detection or prediction of intracranial lesions in CPP cases even though many studies have evaluated the usefulness of the luteinizing hormone (LH), bone age (BA), and Tanner stage.\textsuperscript{2-6} Several studies have reported a higher proportion of brain anomalies in CPP patients in whom puberty started at age 6 years or younger.\textsuperscript{7,8} Therefore, there is no confusion regarding the use of brain MRI for CPP patients in whom puberty started at age 6 years or younger. At a conference in 2007, the North American and European Pediatric Endocrinology Societies concluded that all boys with CPP and all girls with CPP younger than 6 years should undergo brain MRI.\textsuperscript{2} However, it is not clear if 6- to 8-year-old girls with CPP should undergo the same.\textsuperscript{2,4,5,9,10} Therefore, the present study aimed to evaluate the prevalence and types of intracranial lesions among girls with CPP, and the necessity for routine brain MRI examinations.

METHODS

Patients
This retrospective cross-sectional study evaluated data on 317 girls who were treated for CPP at the Pediatric Endocrine Unit of Ajou University Hospital (Suwon, Korea) between April 2003 and December 2016. During that period, 3,528 girls were diagnosed with CPP. The inclusion criteria were a diagnosis of CPP and completion of sellar MRI. Exclusion criteria were the presence of neurofibromatosis, congenital adrenal hyperplasia associated with precocious puberty, a previously identified brain tumor, hydrocephalus, trauma, and absence of MRI data.

Diagnosis of CPP and clinical evaluation
CPP was diagnosed based on a clinical evaluation, including a full medical history of the patient and her caregivers, which was followed by an examination and Tanner staging by a pediatric endocrinologist. CPP was diagnosed after it was confirmed that the patient developed breasts before age 8 years, and had BA advancement > 2 standard deviations (SD) above her chronological age (CA) and a peak LH level ≥ 5 mIU/mL after a gonadotropin-releasing hormone (GnRH) stimulation test.\textsuperscript{7} Height was measured to the nearest 0.1 cm using a Harpenden stadiometer (Holtain Ltd.; Crymych, Wales, UK). Weight was measured to the nearest 0.1 kg using a digital scale. Body mass index (BMI) was calculated as kg/m\textsuperscript{2}. The standard deviations scores (SDS) for height, weight, and BMI were calculated based on the 2007 Korean National Growth Charts.\textsuperscript{8} BA was assessed via radiography of the left hand based on the methods of Greulich and Pyle. Serum LH and follicle stimulating hormone (FSH) levels were measured using immunoradiometric assays (BioSource; Nivelles, Belgium), which has detection limits of 0.1 IU/L and 0.2 IU/L, respectively. Estradiol (E2) levels were measured using a radioimmunoassay; however, during the study period, no statistical calculations were performed due to changes in the reference range owing to changes in the estradiol measurement kit. The GnRH stimulation test was performed during the day, and serum LH and FSH levels were determined at, 30, 45, 60, and 90 minutes after the GnRH injection (100 µg Relefact; Sanofi-Aventis; Frankfurt, Germany).

Sellar MRI
Of the 3,528 girls diagnosed with CPP, 317 girls underwent sellar MRI (Fig. 1). Gadolinium-enhanced T1- and T2-weighted images in the axial, coronal, and sagittal sections were obtained before and after sellar MRI. The sellar MRI examination was performed using two kinds of machines depending on the time period. Prior to 2016, a GE scanner with 1.5- and
3.0-Tesla magnets (Philips Gyroscan-NT; Philips, Eindhoven, The Netherlands) was used; after 2016, a GE scanner with a 3.0-Tesla magnet (Philips Gyroscan-NT; Philips) was used. At our hospital, the indications for sellar MRI among girls with CPP were as follows: children younger than 6 years; girls 6 years or older with parents who wanted their child to undergo sellar MRI when they learned about the relationship between brain lesions and CPP; and girls with central nervous system (CNS)-related symptoms. Patients with a known brain tumor (n = 1) or who refused to undergo MRI (n = 1) were excluded from the analysis. The remaining patients were categorized according to age: younger than 6 years (n = 55), 6–7 years (n = 129), and 7 years or older (n = 133). Routine sellar MRI was performed for girls with CPP who were younger than 6 years. However, we do not recommend routine sellar MRI for all girls who are 6 years or older because they are less likely to have brain lesions. We explained the relationship between brain lesions and CPP to the patients’ parents, and sellar MRI was performed when the parents indicated so.

**Statistical analysis**

Statistical analyses were performed using IBM SPSS software (version 21.0; IBM Corp., Armonk, NY, USA). The results were reported as the mean ± SD, unless stated otherwise. A Mann-Whitney U test was used to compare the characteristics of the diagnostic groups. Statistical significance was defined as $P < 0.05$.

**Ethics statement**

The study protocol was approved by the Institutional Review Board (IRB) of the Ajou University Hospital (IRB No. AJIRB-MED-MDB-16-459). The requirement for informed consent was waived owing to the retrospective nature of this study. This research was conducted in accordance with the principles of the Declaration of Helsinki.

---

**Fig. 1. Study flow chart.**

CPP = central precocious puberty, MRI = magnetic resonance imaging.
RESULTS

The sellar MRI findings of the 317 girls with CPP are presented according to age group in Table 1. MRI revealed CNS abnormalities in 26 girls (8.2%). Imaging studies revealed the presence of Rathke’s cleft cyst (n = 7), pineal cyst (n = 2), suspected pituitary gland hyperplasia (n = 12), suspected pituitary hypoplasia (n = 2), and suspected microadenoma (n = 3). The clinical and biochemical characteristics of the patients with normal and incidental findings are presented in Table 2. There were no significant differences in the mean age at diagnosis, height SDS, weight SDS, BMI SDS, Tanner stage, BA SDS, BA-CA, basal LH levels, peak LH levels, peak FSH levels, and the peak LH/FSH ratio. Patients with incidental findings underwent MRI scans during the follow-up period (mean, 6 months) and others who did not undergo MRI were followed-up clinically (Table 3). None of the girls exhibited CNS-related symptoms or underwent surgery.

DISCUSSION

Previous studies have indicated that the most common intracranial abnormalities associated with CPP are hypothalamic hamartoma, glioma, astrocytoma, and pinealoma. However, the present study did not detect any pathological lesions among girls with CPP, regardless of their

Table 1. Characteristics of the patients according to age at puberty onset

| Characteristics                      | Age at investigation, yr |
|--------------------------------------|--------------------------|
|                                      | < 6 (n = 56) | 6–6.9 (n = 129) | ≥ 7 (n = 133) |
| Normal findings (n = 291)            |             |                |               |
| No relevant finding                  | 53          | 118            | 120           |
| Incidental findings (n = 26)         |             |                |               |
| Rathke’s cleft cyst                  | 1           | 4              | 2             |
| Pineal cyst                          | 0           | 2              | 0             |
| Suspected pituitary gland hyperplasia| 1           | 2              | 9             |
| Suspected pituitary hypoplasia       | 0           | 2              | 0             |
| Suspected microadenoma               | 0           | 1              | 2             |
| Known pathological findings (n = 1)*  | 1           | 0              | 0             |

*Patients with known pathological findings were excluded.

Table 2. Clinical and biochemical characteristics according to brain MRI findings

| Variables                     | Total (n = 317) | Group A (n = 291) | Group B (n = 26) | P value |
|-------------------------------|-----------------|-------------------|------------------|---------|
| Age at diagnosis, yr          | 6.89 ± 1.60     | 6.87 ± 1.57       | 7.17 ± 1.49      | 0.83    |
| Height, SDS                   | 1.07 ± 1.11     | 1.06 ± 1.11       | 1.15 ± 1.09      | 0.14    |
| Weight, SDS                   | 0.83 ± 1.06     | 0.82 ± 1.06       | 0.87 ± 1.07      | 0.07    |
| BMI, SDS                      | 0.43 ± 0.97     | 0.44 ± 0.96       | 0.32 ± 1.15      | 0.07    |
| Tanner stage                  |                 |                   |                  |         |
| Breast                        | 2.25 ± 0.54     | 2.24 ± 0.52       | 2.42 ± 0.70      | 0.15    |
| Pubic hair                    | 1.03 ± 0.19     | 1.02 ± 1.28       | 1.48 ± 1.99      | 0.62    |
| BA, SDS                       | 4.03 ± 1.53     | 4.03 ± 1.43       | 4.09 ± 2.42      | 0.15    |
| BA-CA, yr                     | 2.18 ± 0.83     | 2.18 ± 0.83       | 2.18 ± 0.84      | 0.98    |
| Basal LH, mIU/mL              | 1.05 ± 1.36     | 1.01 ± 1.28       | 1.48 ± 1.99      | 0.17    |
| Peak LH, mIU/mL               | 23.55 ± 25.40   | 23.60 ± 25.60     | 21.86 ± 17.91    | 0.84    |
| Peak FSH, mIU/mL              | 16.07 ± 6.62    | 16.07 ± 6.65      | 16.02 ± 6.38     | 0.97    |
| Peak LH/FSH                   | 1.75 ± 1.86     | 1.65 ± 1.74       | 2.83 ± 2.67      | 0.06    |

Group A, the group with normal findings during the brain magnetic resonance imaging; Group B, the group with new abnormal findings during the brain magnetic resonance imaging.

MRI = magnetic resonance imaging, SDS = standard deviation scores, BMI = body mass index, BA = bone age, CA = chronological age, LH = luteinizing hormone, FSH = follicle stimulating hormone.
In this single-center cohort of 367 consecutive healthy and neurologically asymptomatic girls with precocious puberty, none had newly diagnosed pathological brain lesions. The only CPP-related incidental findings were Rathke’s cleft cyst and pineal cyst. A possible association between CPP and Rathke’s cleft cyst has been reported in previous studies\textsuperscript{12,13}; however, this condition rarely affects children and adolescents, and the incidence of pediatric Rathke’s cleft cyst is unknown.\textsuperscript{14} Jung et al.\textsuperscript{15} and Lim and Yang\textsuperscript{12} reported that 36 of 91 patients (39.5%) and 8 of 44 patients (18.1%) with Rathke’s cleft cyst also had CPP; however, we identified Rathke’s cleft cyst in only 7 of the 367 patients with CPP (1.9%). Our patients did not have any clinical symptoms of Rathke’s cleft cyst and did not require treatment. Pineal cysts commonly occur in pediatric populations, with a higher prevalence observed among girls and older patients.\textsuperscript{16} These cysts can occasionally cause precocious puberty among girls. We detected cases of suspected pituitary gland hyperplasia, which is a frequent cause of incidental findings and may cause precocious puberty; however, the incidence of pituitary hyperplasia in the general population is unknown.\textsuperscript{17} In the present study, pituitary hyperplasia was considered to be a bulging contour of the pituitary gland with a height greater than 6 mm.\textsuperscript{18} Patients who underwent MRI at 6–12 months after their diagnosis and others who did not undergo MRI were followed-up clinically; no pituitary gland changes or clinical findings suggestive of pituitary adenoma were observed. Kornreich et al.\textsuperscript{7} found that CPP causes the pituitary to be prematurely larger than the reference range for age. Therefore, the patients with suspected pituitary gland hyperplasia likely had normal glands. We also detected cases of suspected pituitary hypoplasia and microadenoma, although no studies have reported on these conditions in CPP. The cases of suspected

### Table 3. Characteristics of CPP patients with incidental findings

| Patient | MRI findings                     | Age at diagnosis, yr | Pubertal stage | Height, SDS | Weight, SDS | BMI, SDS | BA-CA, yr | Peak LH, mIU/mL | Clinical course | Clinical follow-up period, yr |
|---------|----------------------------------|----------------------|----------------|------------|-------------|----------|-----------|------------------|----------------|-------------------------------|
| 1       | Pineal gland cyst                | 6.60                 | B2 1P          | −0.02      | 0.50        | 0.65     | 2.40      | 9.10             | Clinical follow-up          | 2.70                          |
| 2       |                                  | 6.60                 | B2 1P          | 0.84       | 0.12        | −0.56    | 1.90      | 7.40             | Clinical follow-up          | 2.10                          |
| 3       | Rathke’s pouch cyst              | 5.70                 | B2 1P          | 0.53       | −1.09       | −2.22    | 1.80      | 12.30            | Clinical follow-up          | 4.20                          |
| 4       |                                  | 6.10                 | B2 1P          | 0.61       | −1.29       | −2.47    | 1.40      | 13.20            | Clinical follow-up          | 3.80                          |
| 5       |                                  | 6.25                 | B2 1P          | 2.83       | 1.69        | 0.53     | 2.25      | 11.0             | Clinical follow-up          | 4.30                          |
| 6       |                                  | 6.70                 | B2 1P          | 0.94       | 0.05        | −0.04    | 1.30      | 14.50            | Clinical follow-up          | 3.40                          |
| 7       |                                  | 6.80                 | B2 1P          | −0.54      | 0.80        | 1.35     | 0.95      | 34.60            | Clinical follow-up          | 1.80                          |
| 8       |                                  | 7.80                 | B2 1P          | 1.78       | 1.25        | 0.61     | 2.20      | 60.80            | MRI follow-up\textsuperscript{a} | 3.50                          |
| 9       |                                  | 8.46                 | B2 1P          | −2.18      | −0.40       | 0.88     | 1.29      | 34.60            | Clinical follow-up          | 1.80                          |
| 10      | Suspicions of microadenoma        | 6.20                 | B2 1P          | 1.15       | 0.74        | 0.12     | 1.05      | 5.60             | MRI follow-up\textsuperscript{a} | 3.70                          |
| 11      |                                  | 8.60                 | B3 1P          | −0.22      | −0.13       | −0.03    | 2.30      | 36.20            | Clinical follow-up          | 2.10                          |
| 12      |                                  | 8.90                 | B3 1P          | 1.59       | 1.27        | 0.82     | 2.60      | 73.70            | Clinical follow-up          | 1.60                          |
| 13      | Suspicions of pituitary gland hyperplasia | 1.80   | B4 1P          | 1.81       | 3.14        | NA       | 3.70      | 102.20           | MRI follow-up\textsuperscript{a} | 9.20                          |
| 14      |                                  | 6.75                 | B3 1P          | 2.47       | 2.06        | 1.45     | 1.25      | 7.90             | MRI follow-up\textsuperscript{a} | 1.10                          |
| 15      |                                  | 6.75                 | B2 1P          | 0.85       | 0.02        | −0.72    | 2.25      | 5.20             | Clinical follow-up          | 5.80                          |
| 16      |                                  | 7.30                 | B2 2P          | 1.27       | 2.07        | 2.10     | 4.20      | 88.10            | Clinical follow-up          | 2.50                          |
| 17      |                                  | 7.40                 | B3 1P          | 2.38       | 1.28        | 0.24     | 1.60      | 24.30            | Clinical follow-up          | 4.60                          |
| 18      |                                  | 7.50                 | B2 1P          | 1.25       | 0.65        | 0.01     | 2.00      | 40.50            | MRI follow-up\textsuperscript{a} | 2.60                          |
| 19      |                                  | 8.00                 | B2 1P          | 2.02       | 1.77        | 1.30     | 3.50      | 63.60            | MRI follow-up\textsuperscript{a} | 4.30                          |
| 20      |                                  | 8.40                 | B3 1P          | 1.48       | 1.73        | 1.54     | 3.10      | 55.80            | MRI follow-up\textsuperscript{a} | 0.90                          |
| 21      |                                  | 8.60                 | B3 1P          | 0.47       | 0.28        | 0.07     | 2.40      | 35.10            | MRI follow-up\textsuperscript{a} | 2.60                          |
| 22      |                                  | 8.75                 | B4 3P          | 2.45       | 2.01        | 1.42     | 2.75      | 37.20            | Clinical follow-up          | 2.10                          |
| 23      |                                  | 8.80                 | B2 1P          | 0.86       | 0.27        | −0.21    | 1.95      | 41.30            | Clinical follow-up          | 2.80                          |
| 24      |                                  | 8.80                 | B4 1P          | 1.78       | 2.20        | 2.04     | 2.70      | 104.00           | MRI follow-up\textsuperscript{a} | 2.50                          |
| 25      | Suspicions of pituitary hypoplasia | 6.30   | B2 1P          | 1.91       | 1.51        | 0.83     | 1.70      | 5.70             | Clinical follow-up          | 6.90                          |
| 26      |                                  | 6.50                 | B2 1P          | 1.55       | 0.05        | −1.32    | 1.75      | 8.80             | Clinical follow-up          | 0.50                          |

CPP = central precocious puberty, MRI = magnetic resonance imaging, SDS = standard deviation scores, BMI = body mass index, BA = bone age, CA = chronological age, LH = luteinizing hormone, B = Breast, P = Pubic hair, NA = not available.

\textsuperscript{a}Unchanged, \textsuperscript{b}Normal.
pituitary hypoplasia and microadenoma did not exhibit clinical symptoms, and it is difficult to draw conclusions regarding the relevance of these findings. Nevertheless, all the MRI findings in the present study may apply to healthy individuals as well; therefore, it remains unclear if they were causally related to CPP.

Many studies have examined the need for brain MRI in patients with CPP, and have attempted to identify the predictors associated with pathological intracranial abnormalities.\textsuperscript{4,10,19-21} For example, Ng et al.\textsuperscript{10} evaluated 67 girls in whom the mean age at the reported time of CPP onset was 6.2 years (range 2.0–7.9) and who were diagnosed with CPP using brain MRI; they concluded that cranial MRJ scans were indicated for all girls with CPP because 15% of these girls had intracranial lesions that were not predicted by any of the examined factors (e.g., onset of puberty, pubertal stage, BA advancement, pelvic ultrasound findings, and GnRH stimulation test results). None of those patients had neurologic abnormalities at initial presentation. A study on 208 girls with CPP performed in Copenhagen (1993–2009)\textsuperscript{4} revealed that 20 girls (9.6%) had incidental findings (e.g., pineal cyst or pituitary microadenoma), and 13 (6.3%) had pathological findings (e.g., arachnoid cyst, hypothalamic hematoma, and pilocytic astrocytoma). However, none of the patients had CNS signs or symptoms, and only one patient (0.5%) required surgery. Nevertheless, the researchers concluded that 6- to 8-year-old girls with CPP had a high frequency of intracranial lesions that were not associated with any useful predictors; in addition, they concluded that these girls should undergo brain MRI. In contrast, Bridges et al.\textsuperscript{3} reported that of 96 girls with CPP, CNS abnormalities were found in only one patient with known brain lesions, and they concluded that an indication for brain MRI could not be justified based on the improved management of children with CPP alone. In addition, Pedicelli et al.\textsuperscript{5} evaluated 182 girls with CPP during 1990–2012, and reported that 157 patients (86%) had normal findings, 19 (11%) had incidental findings, and 6 (3%) had pathological CNS abnormalities (e.g., hamartoma) that were detected before age 6 years and did not require surgery. None of the patients had signs or symptoms of CNS lesions. Therefore, Pedicelli et al.\textsuperscript{5} concluded that intracranial pathologies occur rarely among girls with CPP older than 6 years.

The present study revealed results similar to those of previous studies. This may be related to the increasing incidence of CPP reported in the United States, Europe, China, and Korea.\textsuperscript{22-24} Furthermore, the annual incidence of CPP has substantially increased among Korean girls over the past 7 years, and the incidence among girls aged 6 years or older is significantly higher than that among girls younger than 6 years.\textsuperscript{23} Based on the results of the present study, this finding was most likely caused by an increase in the idiopathic form of CPP rather than an increase in the frequency of brain lesions.

Some researchers believe that routine brain MRI is unnecessary for 6- to 8-year-old girls with CPP, and our findings support this view. Our center does not routinely perform sellar MRI for all children older than 6 years who are diagnosed with CPP. The researchers at our center explained the relationship between CPP and brain lesions to the parents of girls with CPP. Then, they performed sellar MRI only if the parents wanted it. Therefore, only 317 of 3,528 patients who were 6–8 years old underwent MRI. The remaining patients did not undergo sellar MRI and were diagnosed with suspected idiopathic CPP and treated with a GnRH agonist. They consistently underwent physical examinations for neurological symptoms. The 3,200 girls with suspected idiopathic CPP who did not undergo MRI had a mean follow-up period of 28.51 ± 17.09 months (range, 1–131 months), and none of these patients developed signs of intracranial lesions during the study period.
There is a consensus that girls who develop CPP before the age of 6 years may have a CNS lesion, and CPP in these cases is likely caused by a brain lesion. Therefore, we typically perform MRI for children who develop CPP before age 6 years. However, we found that none of the girls younger than 6 years with newly diagnosed CPP had a pathological brain lesion, with the exception of one 6-year-old girl with CPP who had a choroid plexus papilloma that was diagnosed at age 6 months. Despite its single-center design, this study identified 55 patients who were younger than 6 years and had CPP, which is comparable to the sample sizes of previous studies. Although we cannot definitively calculate the prevalence of CPP with concurrent intracranial lesions among children younger than 6 years, we believe that it is important to note the discrepancy between our findings and those of previous studies. This discrepancy does not change the need to screen CPP patients younger than 6 years for brain lesions, even with the absence of useful predictive factors; however, it is important to consider if the prevalence of CPP with concurrent brain lesions is overestimated.

Although CPP can be related to brain pathologies, relatively few cases require surgical intervention, and there is a relatively low risk associated with minor abnormalities and incidental findings. It may be unnecessary to routinely perform MRI to detect non-interventional conditions, especially because it is expensive and places an economic burden on patients. Therefore, the low frequency of the detection of interventional conditions may indicate that sellar MRI is not cost-effective. The non-routine use of MRI for patients with CPP was associated with savings of approximately USD 2,230,000 (USD 700/person during 2003–2016). Furthermore, no clinical findings were suggestive of brain lesions in patients who did not undergo sellar MRI, which indirectly confirms that there were no intracranial lesions that required intervention. Therefore, we believe that it may be appropriate to educate the parents of patients with CPP regarding the low probability of their children having dangerous brain pathologies. These parents could be guided away from routine MRI and toward simpler monitoring methods, such as continuous monitoring for neurological symptoms and altered growth status.9,10

The present study had several limitations. First, it evaluated the patients’ ages at the time of the diagnosis, and the precise onset of secondary sexual characteristic development was unknown because the parents did not report the age at onset. Therefore, the onset of secondary sexual characteristic development would have occurred at ages younger than those we identified. In addition, although the patients’ mothers did precisely report the age at first menstruation, the maternal age of menarche could not be identified. Second, a single-center design is associated with known risks of bias, although we believe that the large sample size and prolonged study period support the validity of our findings. Third, the prevalence of brain lesions among patients who did not undergo sellar MRI remains unclear, although the long-term follow-up results indicated that there were no intracranial lesions that required intervention. However, the results of 3,200 patients who have not undergone sellar MRI are not negligible considering the study population, but this limitation did not affect the outcomes of the 317 patients who underwent sellar MRI. Therefore, these results support our belief that routine brain MRI may be unnecessary for 6- to 8-year-old girls with CPP. Finally, we examined only Korean children. Therefore, it is possible that the regional prevalence of brain lesions in CPP cases is related to the studied population, race, medical system, and social factors (e.g., access to medical care and resources for diagnosing CPP). As no new trends in the prevalence associated with brain lesions and CPP have been reported in the past decade, re-evaluations should be performed in other countries.
In conclusion, the present study revealed that the previously reported prevalence of cerebral lesions among girls with CPP was much higher than the prevalence observed at our center. Although it is possible that there are regional or racial differences in the prevalence of CPP, we believe that the prevalence of pathological cerebral lesions among CPP cases is overestimated and should be re-evaluated. Furthermore, it may be prudent to reconsider the routine use of brain MRI to screen all patients with CPP, especially if they are healthy and neurologically asymptomatic, and in the case of girls aged 6–8 years.

REFERENCES

1. Kliegman RM, Stanton B, Geme JW, Schor NF, Behrman RE. *Nelson Textbook of Pediatrics, 20th ed.* Philadelphia, PA: Elsevier; 2016.

2. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Antoniazzi F, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. *Pediatrics* 2009;123(4):e752-62.

3. Bridges NA, Christopher JA, Hindmarsh PC, Brook CG. Sexual precocity: sex incidence and aetiology. *Arch Dis Child* 1994;70(2):116-8.

4. Mogensen SS, Aksela L, Mouritsen A, Sørensen K, Gideon P, et al. Pathological and incidental findings on brain MRI in a single-center study of 229 consecutive girls with early or precocious puberty. *PLoS One* 2012;7(1):e29820.

5. Pedicelli S, Alessio P, Sciré G, Cappa M, Cianfarani S. Routine screening by brain magnetic resonance imaging is not indicated in every girl with onset of puberty between the ages of 6 and 8 years. *J Clin Endocrinol Metab* 2014;99(12):4455-61.

6. Cisternino M, Arrigo T, Pasquino AM, Tinelli C, Antoniazzi F, Beduschi L, et al. Etiology and age incidence of precocious puberty in girls: a multicentric study. *J Pediatr Endocrinol Metab* 2000;13 Suppl 1:695-701.

7. Kornreich L, Horev G, Blaser S, Daneman D, Kauli R, Grunebaum M. Central precocious puberty: evaluation by neuroimaging. *Pediatr Radiol* 1995;25(1):7-11.

8. Cassio A, Cacciari E, Zucchini S, Balsamo A, Diegoli M, Bolognini F. Central precocious puberty: clinical and imaging aspects. *J Pediatr Endocrinol Metab* 2000;13 Suppl 1:703-8.

9. Kaplowitz PB. Do 6-8 year old girls with central precocious puberty need routine brain imaging? *Int J Pediatr Endocrinol* 2016;2016(1):9.

10. Ng SM, Kumar Y, Cady D, Smith CS, Didi M. Cranial MRI scans are indicated in all girls with central precocious puberty. *Arch Dis Child* 2003;88(5):414-8.

11. Carel JC, Léger J. Clinical practice. Precocious puberty. *N Engl J Med* 2008;358(22):2366-77.

12. Lim HH, Yang SW. Risk factor for pituitary dysfunction in children and adolescents with Rathke’s cleft cysts. *Korean J Pediatr* 2010;53(7):759-65.

13. Trifanescu R, Ansonore O, Wass JA, Grossman AB, Karavitaki N. Rathke’s cleft cysts. *Clin Endocrinol (Oxf)* 2012;76(2):151-60.

14. Zada G, Ditty B, McNatt SA, McComb SG, Krieger MD. Surgical treatment of rathke cleft cysts in children. *Neurosurgery* 2009;64(6):1132-7.

15. Jung JE, Jin J, Jung MK, Kwon A, Chae HW, Kim DH, et al. Clinical manifestations of Rathke’s cleft cysts and their natural progression during 2 years in children and adolescents. *Ann Pediatr Endocrinol Metab* 2017;22(3):164-9.
16. Al-Holou WN, Garton HJ, Muraszko KM, Ibrahim M, Maher CO. Prevalence of pineal cysts in children and young adults. *J Neurosurg Pediatr* 2009;4(3):230-6.

17. Al-Gahtany M, Horvath E, Kovacs K. Pituitary hyperplasia. *Hormones (Athens)* 2003;2(3):149-58.

18. Elster AD, Chen MY, Williams DW 3rd, Key LL. Pituitary gland: MR imaging of physiologic hypertrophy in adolescence. *Radiology* 1990;174(3 Pt 1):681-5.

19. Chalumeau M, Chemaitilly W, Trivin C, Adan L, Bréart G, Brauner R. Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities. *Pediatrics* 2002;109(1):64-7.

20. Choi KH, Chang SJ, Kang MJ, Yoon JY, Lee JE, Lee YA, et al. Boys with precocious or early puberty: incidence of pathological brain magnetic resonance imaging findings and factors related to newly developed brain lesions. *Ann Pediatr Endocrinol Metab* 2013;18(4):183-90.

21. Trivin C, Couto-Silva AC, Sainte-Rose C, Chemaitilly W, Kalifa C, Doz F, et al. Presentation and evolution of organic central precocious puberty according to the type of CNS lesion. *Clin Endocrinol (Oxf)* 2006;65(2):239-45.

22. Talma H, Schönbeck Y, van Dommelen P, Bakker B, van Buuren S, Hirasing RA. Trends in menarcheal age between 1955 and 2009 in the Netherlands. *PLoS One* 2013;8(4):e60056.

23. Kim SH, Huh K, Won S, Lee KW, Park MI. A significant increase in the incidence of central precocious puberty among Korean girls from 2004 to 2010. *PLoS One* 2015;10(11):e0141844.

24. Aksglaede L, Sørensen K, Petersen JH, Skakkebaek NE, Juul A. Recent decline in age at breast development: the Copenhagen Puberty Study. *Pediatrics* 2009;123(5):e932-9.